Our results suggest that high expression levels of LMP2, PSME1 and PSME2 are associated with positive prognosis in NSCLC patients, and the sensitivity of NSCLC patients to NACI treatment can be predicted in advance by protein expression intensity, thus helping clinicians treat patients more effectively. The gene discussed is PSME2; the disease is non-small cell lung carcinoma.